Journal Article
. 2017 Jun; 165(1):65-76.
doi: 10.1007/s10549-017-4326-1.

The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis

Gulisa Turashvili 1 Edi Brogi 1 Monica Morrow 2 Clifford Hudis 3 Maura Dickler 3 Larry Norton 3 Hannah Y Wen 4 
Affiliations
  • PMID: 28577081
  •     59 References
  •     4 citations

Abstract

Background/Purpose: The 21-gene recurrence score (RS) assay predicts the likelihood of distant recurrence and chemotherapy benefit in early-stage, estrogen receptor (ER)-positive, HER2-negative breast cancer. Data on the RS of special histologic subtypes of invasive breast carcinoma with favorable prognosis are limited.

Methods: We reviewed our institutional database to identify patients with special histologic subtypes of breast cancer associated with favorable prognosis and available RS results. Our cohort consists of fifty-seven women: thirty-three patients with pure mucinous carcinoma (MC), ten with tubular carcinoma (TC), nine with encapsulated papillary carcinoma (EPC), and five with solid papillary carcinoma (SPC).

Results: Most (44/57, 77.2%) carcinomas had low RS (≤17), and none had high RS (≥31). All EPCs had low RS, but other subtypes had RS 18-30. Higher RS was associated with lower progesterone receptor (PR) expression by immunohistochemistry and lower PR mRNA scores (P ≤ 0.007). No morphologic feature (tumor grade, biopsy site changes, cellular stroma, inflammatory cells) was associated with RS ≥ 18. At a median follow-up of 40 months, the distant recurrence-free survival was 100%. One patient with SPC developed locoregional recurrence at 22 months.

Conclusions: As the largest series to date, our study raises the question of whether the RS assay is necessary for breast cancers with favorable histology. Reflex testing of node-negative, ER+/HER2- breast cancers may be deferred for these special histologic subtypes, emphasizing the need for multidisciplinary discussions between breast pathologists and other members of the breast cancer team.

Keywords: 21-gene recurrence score assay; Breast cancer; Encapsulated papillary carcinoma; Favorable histology; Mucinous carcinoma; Solid papillary carcinoma; Tubular carcinoma.

Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes.
Scott D Ramsey, William E Barlow, +6 authors, Gabriel N Hortobagyi.
Contemp Clin Trials, 2012 Sep 25; 34(1). PMID: 23000081    Free PMC article.
Review.
Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas.
Maria A Lopez-Garcia, Felipe C Geyer, +5 authors, Britta Weigelt.
J Pathol, 2010 Jul 02; 222(1). PMID: 20593406
Mucinous micropapillary carcinoma of the breast: an aggressive counterpart to conventional pure mucinous tumors.
Violetta Barbashina, Adriana D Corben, +2 authors, Lee K Tan.
Hum Pathol, 2013 Mar 23; 44(8). PMID: 23517923
Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
A S Coates, E P Winer, +6 authors, Panel Members.
Ann Oncol, 2015 May 06; 26(8). PMID: 25939896    Free PMC article.
Highly Cited.
Are encapsulated papillary carcinomas of the breast in situ or invasive? A basement membrane study of 27 cases.
Nicole Nicosia Esposito, David J Dabbs, Rohit Bhargava.
Am J Clin Pathol, 2009 Jan 15; 131(2). PMID: 19141383
The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort.
Foluso O Ademuyiwa, Austin Miller, +5 authors, Sunil Badve.
Breast Cancer Res Treat, 2011 Jan 05; 126(3). PMID: 21197567
Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.
Molly E Klein, David J Dabbs, +4 authors, Rohit Bhargava.
Mod Pathol, 2013 Mar 19; 26(5). PMID: 23503643    Free PMC article.
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.
Michael J Hassett, Samuel M Silver, +12 authors, Jane C Weeks.
J Clin Oncol, 2012 May 16; 30(18). PMID: 22585699    Free PMC article.
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up.
P P Rosen, S Groshen, D W Kinne, L Norton.
J Clin Oncol, 1993 Nov 01; 11(11). PMID: 8229123
The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.
Jennifer E Joh, Nicole N Esposito, +10 authors, Geza Acs.
Oncologist, 2011 Oct 22; 16(11). PMID: 22016474    Free PMC article.
Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
Jena Auerbach, Mimi Kim, Susan Fineberg.
Arch Pathol Lab Med, 2010 Nov 04; 134(11). PMID: 21043825
Histopathologic variables predict Oncotype DX recurrence score.
Melina B Flanagan, David J Dabbs, +2 authors, Rohit Bhargava.
Mod Pathol, 2008 Mar 25; 21(10). PMID: 18360352
Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.
Bernhard C Pestalozzi, David Zahrieh, +13 authors, International Breast Cancer Study Group.
J Clin Oncol, 2008 May 07; 26(18). PMID: 18458044
Breast intracystic papillary carcinoma: an update.
Julien Calderaro, Marc Espie, +7 authors, Anne de Roquancourt.
Breast J, 2009 Sep 09; 15(6). PMID: 19735389
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
Shelly S Lo, Patricia B Mumby, +8 authors, Kathy S Albain.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065191
Highly Cited.
Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
Joseph T Rabban, Frederick C Koerner, Melinda F Lerwill.
Hum Pathol, 2006 Jun 21; 37(7). PMID: 16784976
Prediction of Low versus High Recurrence Scores in Estrogen Receptor-Positive, Lymph Node-Negative Invasive Breast Cancer on the Basis of Radiologic-Pathologic Features: Comparison with Oncotype DX Test Recurrence Scores.
Vandana Dialani, Shantanu Gaur, +5 authors, Priscilla J Slanetz.
Radiology, 2016 Mar 05; 280(2). PMID: 26937802
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.
Valentina I Petkov, Dave P Miller, +21 authors, Steven Shak.
NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721379    Free PMC article.
Highly Cited.
Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?
Séverine Guiu, Anita Wolfer, +4 authors, Maryse Fiche.
Crit Rev Oncol Hematol, 2014 Aug 19; 92(3). PMID: 25129506
Review.
Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
Mark N Levine, Jim A Julian, +5 authors, Kathleen I Pritchard.
J Clin Oncol, 2015 Nov 26; 34(10). PMID: 26598746
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.
J Albanell, A González, +17 authors, A Lluch.
Ann Oncol, 2011 Jun 10; 23(3). PMID: 21652577
Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Michaela A Dinan, Xiaojuan Mi, +2 authors, Lesley H Curtis.
JAMA Oncol, 2015 Aug 28; 1(8). PMID: 26313372
Clinicopathologic Characteristics of Solid Papillary Carcinoma of the Breast.
Benjamin Yongcheng Tan, Aye Aye Thike, Ian O Ellis, Puay Hoon Tan.
Am J Surg Pathol, 2016 Jul 21; 40(10). PMID: 27438988
The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.
D B Geffen, S Abu-Ghanem, +6 authors, M Koretz.
Ann Oncol, 2011 Mar 03; 22(11). PMID: 21363879
Intracystic papillary carcinoma of the breast: An in situ or invasive tumor? Results of immunohistochemical analysis and clinical follow-up.
Christine A Wynveen, Tatjana Nehhozina, +4 authors, Edi Brogi.
Am J Surg Pathol, 2010 Nov 19; 35(1). PMID: 21084964
The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics.
Tomoya Nagao, Takayuki Kinoshita, +3 authors, Yasuhiro Fujiwara.
Breast, 2012 Jan 27; 21(3). PMID: 22277312
TAILORx: trial assigning individualized options for treatment (Rx).
Joseph A Sparano.
Clin Breast Cancer, 2006 Nov 10; 7(4). PMID: 17092406
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade.
Britta Weigelt, Frederick L Baehner, Jorge S Reis-Filho.
J Pathol, 2009 Nov 21; 220(2). PMID: 19927298
Highly Cited. Review.
Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
Helen Ingoldsby, Mark Webber, +3 authors, Grace Callagy.
Breast, 2013 May 07; 22(5). PMID: 23643806
Solid papillary carcinoma of the breast: a pathologically and clinically distinct breast tumor.
Jinous Saremian, Marilin Rosa.
Arch Pathol Lab Med, 2012 Oct 02; 136(10). PMID: 23020734
Review.
Refinement of breast cancer classification by molecular characterization of histological special types.
B Weigelt, H M Horlings, +7 authors, J L Peterse.
J Pathol, 2008 Aug 23; 216(2). PMID: 18720457
Highly Cited.
Clinicopathologic analysis of solid papillary carcinoma of the breast and associated invasive carcinomas.
Hind Nassar, Hina Qureshi, +2 authors, Daniel Visscher.
Am J Surg Pathol, 2006 Apr 21; 30(4). PMID: 16625097
Papilloma and papillary carcinoma.
Frederick Koerner.
Semin Diagn Pathol, 2010 Mar 24; 27(1). PMID: 20306827
Breast carcinoma--rare types: review of the literature.
R Yerushalmi, M M Hayes, K A Gelmon.
Ann Oncol, 2009 Jul 16; 20(11). PMID: 19602565
Review.
Special types of invasive breast cancer, with clinical implications.
David L Page.
Am J Surg Pathol, 2003 May 27; 27(6). PMID: 12766589
Landmark clinical trials influencing surgical management of non-invasive and invasive breast cancer.
Thomas B Julian, Charis A Venditti, Shivani Duggal.
Breast J, 2014 Dec 19; 21(1). PMID: 25521007
Review.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Personalizing extent of breast cancer surgery according to molecular subtypes.
Monica Morrow.
Breast, 2013 Oct 01; 22 Suppl 2. PMID: 24074769
Review.
A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas.
Geza Acs, Nicole N Esposito, +2 authors, Christine Laronga.
Mod Pathol, 2011 Dec 17; 25(4). PMID: 22173289
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Metastatic potential of encapsulated (intracystic) papillary carcinoma of the breast: a report of 2 cases with axillary lymph node micrometastases.
Anna Marie Mulligan, Frances P O'Malley.
Int J Surg Pathol, 2007 May 05; 15(2). PMID: 17478767
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
W Eiermann, M Rezai, +13 authors, J Blohmer.
Ann Oncol, 2012 Nov 09; 24(3). PMID: 23136233    Free PMC article.
Solid-papillary carcinoma of the breast: clinicopathological study of 20 cases.
Yoshiro Otsuki, Makoto Yamada, +7 authors, Hiroshi Kobayashi.
Pathol Int, 2007 Jun 26; 57(7). PMID: 17587241
Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
Michaela L Tsai, Tamera J Lillemoe, +5 authors, Karen K Swenson.
Clin Breast Cancer, 2015 Sep 20; 16(1). PMID: 26385397
Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients.
Matthew G Hanna, Ira J Bleiweiss, Anupma Nayak, Shabnam Jaffer.
Int J Breast Cancer, 2017 Feb 09; 2017. PMID: 28168058    Free PMC article.
The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
Josh J Carlson, Joshua A Roth.
Breast Cancer Res Treat, 2013 Aug 27; 141(1). PMID: 23974828    Free PMC article.
Highly Cited. Systematic Review.
Comparison of Oncotype DX Recurrence Score by Histologic Types of Breast Carcinoma.
Philip E Bomeisl, Cheryl L Thompson, Lyndsay N Harris, Hannah L Gilmore.
Arch Pathol Lab Med, 2015 Dec 01; 139(12). PMID: 26619027
Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
Bradley M Turner, Kristin A Skinner, +6 authors, David G Hicks.
Mod Pathol, 2015 May 02; 28(7). PMID: 25932962
Encapsulated papillary carcinoma of the breast: an invasive tumor with excellent prognosis.
Emad A Rakha, Nirav Gandhi, +6 authors, Ian O Ellis.
Am J Surg Pathol, 2011 Jul 15; 35(8). PMID: 21753694
Histological types of breast cancer: how special are they?
Britta Weigelt, Felipe C Geyer, Jorge S Reis-Filho.
Mol Oncol, 2010 May 11; 4(3). PMID: 20452298    Free PMC article.
Highly Cited. Review.
Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?
K H Allison, P L Kandalaft, +2 authors, A M Gown.
Breast Cancer Res Treat, 2011 Mar 04; 131(2). PMID: 21369717
Tubular carcinoma of the breast: further evidence to support its excellent prognosis.
Emad A Rakha, Andrew H S Lee, +6 authors, Ian O Ellis.
J Clin Oncol, 2009 Nov 18; 28(1). PMID: 19917872
Biology before Anatomy in Early Breast Cancer--Precisely the Point.
Clifford A Hudis.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412350
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models.
Fabio Parisi, Ana M Gonzalez, +4 authors, Yuval Kluger.
Breast Cancer Res, 2010 Sep 03; 12(5). PMID: 20809974    Free PMC article.
Adjuvant therapies for special types of breast cancer.
Marco Colleoni, Leila Russo, Silvia Dellapasqua.
Breast, 2011 Nov 02; 20 Suppl 3. PMID: 22015285
Review.
Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Jessica F Partin, Eleftherios P Mamounas.
Ann Surg Oncol, 2011 May 04; 18(12). PMID: 21537874
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Breast Cancers of Special Histologic Subtypes Are Biologically Diverse.
Audree B Tadros, Hannah Y Wen, Monica Morrow.
Ann Surg Oncol, 2018 Aug 11; 25(11). PMID: 30094484    Free PMC article.
Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study.
Wei Wang, Xiaosong Chen, +12 authors, Kunwei Shen.
J Cancer, 2018 Oct 03; 9(18). PMID: 30271480    Free PMC article.
The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes.
Jun Wang, Zhen-Yu He, +3 authors, San-Gang Wu.
Front Genet, 2019 Jan 09; 9. PMID: 30619463    Free PMC article.
Mucinous carcinoma with micropapillary features is morphologically, clinically and genetically distinct from pure mucinous carcinoma of breast.
Peng Sun, Zaixuan Zhong, +6 authors, Jiehua He.
Mod Pathol, 2020 May 03; 33(10). PMID: 32358590